){kind=logo}
May 15, 2025 – Research Triangle Park, NC – Kincell Bio announced the completion of a $22 million round, led by…
Kineticos Capital Partners Fund Series Powering the innovative life sciences ecosystem by investing in specialized pharma services, tools and equipment…
Kineticos Disruptor Fund Series We partner with companies advancing breakthrough technologies to tackle cancer, and neurodegenerative and rare diseases.
Antimicrobial Resistance (AMR) Accelerator Fund We invest in innovative technologies and high performing teams to deliver solutions for antimicrobial resistance.
Strategy & Funds We partner with transformative companies and exceptional teams to drive meaningful, long-term impact.
Kinvard is a preclinical biotech with an IV/oral compound targeting gram-negative and positive pathogens, leveraging technology from Harvard University and non-dilutive funding from CARB-X.
)
Kineticos Portfolio Company, Inceptor Bio, Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma…
){kind=logo}
Kineticos Launches Kinvard Bio to Advance Next-Generation Antibiotics in the Fight Against Antimicrobial Resistance Raleigh, North Carolina – February 24,…
Steve Gelone Joins Kineticos as a Strategic Advisor for Kineticos AMR Accelerator Fund I (KAMRA I) Raleigh, North Carolina –…